Biomedical subjects

P Kolarov

Publications and source records attributed to P Kolarov.

At least 19 recordsLinked to original sources

PubMed1996

PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS)

BACKGROUND: Percutaneous transluminal coronary angioplasty (PTCA) with its various manipulations could create a dangerous, sudden haemostatic response. This study was performed to investigate PTCA-induced periprocedural changes in platelet activation and its consequences. METHODS: Twenty-five consecutive patients admitted for elective PTCA were preclassified as having or not having circulating activated platelets. Blood samples were taken for platelet activation marker analysis before, six times during and 2 h after PTCA. Intravascular platelet activation was analysed by flow cytometry to measure activation-dependent surface markers thrombospondin, P-selectin (CD62) and lysosomal GP53 (CD63). RESULTS: PTCA was associated with a significant reduction of peripheral platelet count. The initiation of the PTCA procedure led to a significant loss of more than 50% of the degranulated, activated platelets. After PTCA, the number of degranulated, activated platelets uniformly increased. CONCLUSIONS: We conclude that PTCA can induce consumption, particularly of preactivated platelets, and lead to sustained platelet activation after the procedure. This might explain why preactivated patients are at increased risk of suffering periprocedural ischaemic events and why increased thrombogenicity favours acute flow disruption and the progression of coronary stenosis at the lesion site.

Angioplasty, Balloon, Coronary↗

PubMed1993

Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA.

BACKGROUND: We wished to investigate whether platelet activation is related to the clinical outcome during the 24 hours immediately after elective percutaneous transluminal coronary angioplasty (PTCA). METHODS AND RESULTS: In 102 patients with high-grade coronary stenosis admitted for elective PTCA, preprocedural platelet activation was characterized by flow cytometric measurement of the proteins CD62, CD63, and thrombospondin expressed on the platelet surface membrane. The prevalence of acute ischemic events during the 24 hours immediately after the procedure was then related to the pre-PTCA platelet activation status. Fifty-six patients were classified as "nonactivated," whereas 46 patients showed an increased percentage of activated platelets. Two patients developed acute occlusion (1.96%) and four patients high-grade restenosis (3.92%), as confirmed by second-look coronary angiography. All events occurred in patients classified as "activated" (six of 46, or 13%). None of these patients received beta-blocker medication, which was associated with lower expression of platelet membrane activation markers. In the nonactivated patient group, no clinical events were found (0 of 56, or 0%). This difference in prevalence is significant (p = 0.007). CONCLUSIONS: We conclude that analysis of platelet membrane activation markers may help to predict an increased risk of acute ischemic events after angioplasty.

Angioplasty, Balloon, Coronary↗

PubMed1987

[Glycosylated hemoglobin (HbA1)--an index in the control of diabetes].

A total of 108 patients with diabetes, type II were studied--68 males and 40 females, with an average age of 63 years for the males and 67 years for the females, with various duration--from freshly diagnosed to over 20 years. A positive correlation was established between the serum HbA1 level and blood sugar before meals, its maximum elevation within 24 h and the evaluation of the stage of decompensation of carbohydrate metabolism. Glycemia and HbA1 are not interchangeable but reciprocally complemented indices for diabetes control, for that subjected to follow up care in particular. The state of lipid disorders in diabetes, HbA1 could be used as a marker of synthesis of HDL cholesterol and to a lesser degree--of triglycerides and total cholesterol.

Aged↗

PubMed1978

[Therapeutic effect of Trental in diabetic angiopathy].

The effect of pentoxiphyline substance--Trental, production of Höchst, was studied in 37 diabetics (12 females and 25 males) aged from 36 to 78. Besides according to clinical manifestations, the therapeutic effect was objectivized in dynamics through the oscillography "Gesenius-Keller", double-rheography "Schufrid", skin thermometer--Tastotherm P 60 "Braun" and 6-canal ECG apparatus "Hellige". Favourable results, evaluated according to all mentioned methods were found in 89.2 per cent of the treated 37 patients; excellent effect in 15 of them 40.5%); very good--in 8 (21.6%); good--in 10 (27.1%) 1 and without effect--only 4 patients (10.8%). Trental is concluded to deserve a wide application in the clinical practice for the peripheral diabetic angiopathy treatment in patients with diabetes mellitus.

Adult↗

PubMed1973